WH, L., DJH, T., K, M., MLP, T., CH, N., D, K., . . . MS, S. (2026). Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 24(8), 2181-2190. https://doi.org/10.1016/j.cgh.2025.10.016
Παραπομπή σε μορφή Chicago (17η εκδ.)WH, Lim, et al. "Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates." Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 24, no. 8 (2026): 2181-2190. https://doi.org/10.1016/j.cgh.2025.10.016.
Παραπομπή σε μορφή MLA (9th εκδ.)WH, Lim, et al. "Impact of Model for End-Stage Liver Disease 3.0 on Waitlist Outcomes of Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis Among Liver Transplant Candidates." Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association, vol. 24, no. 8, 2026, pp. 2181-2190, https://doi.org/10.1016/j.cgh.2025.10.016.